4 Big Stocks to Add to Your Buy List

4 Big Stocks to Add to Your Buy List

Here’s a technical look at how to trade some of the most active stocks on the market right now.

Put down the 10-K filings and the stock screeners. It’s time to take a break from the traditional methods of generating investment ideas. Instead, let the crowd do it for you.

From hedge funds to individual investors, scores of market participants are turning to social media to figure out which stocks are worth watching. It’s a concept that’s known as “crowdsourcing,” and it uses the masses to identify emerging trends in the market.

Crowdsourcing has long been a popular tool for the advertising industry, but it also makes a lot of sense as an investment tool. After all, the market is completely driven by the supply and demand, so it can be valuable to see what names are trending among the crowd.

While some fund managers are already trying to leverage social media resources like Twitter to find algorithmic trading opportunities, for most investors, crowdsourcing works best as a starting point for investors who want a starting point in their analysis.

Today, we’ll leverage the power of the crowd to take a look at some of the most active stocks on the market.

Small-cap biotech stock Vitae Pharmaceuticals  (VTAE)  is up more than 158% this afternoon, boosted following news that Allergan  (AGN)  (which is a holding in Jim Cramer’s Action Alerts PLUS charitable portfolio) was offering to buy the smaller company for $21 per share in cash. That is driving enough volume in to Vitae to make this small firm one of the most actively traded stocks on the Nasdaq this morning.

The deal adds Vitae’s psoriasis and dermatitis treatments to Allergan’s pipeline, filling out the company’s skin health offerings. Allergan sees the deal closing by year-end — and the near-immediate gap up to the offer price this morning signals that Wall Street is pricing in a high likelihood of the deal getting done.

For traders who missed the buyout, the money has already been made on the VTAE trade.

Apple  (AAPL)  , a holding in Jim Cramer’s Action Alerts PLUS charitable portfolio, is up 4% on big volume as I write this afternoon, rallying following early presales numbers for the firm’s iPhone 7 and iPhone 7 Plus, which were reported by T-Mobile  (TMUS)  and Sprint  (S)  yesterday. T-Mobile CEO John Legere reported that sales were “like four times bigger than the iPhone 6 for us at the pre-order stage,” with Sprint adding that preorders for the next-gen phones are up 375% versus the same period last year. That sneak peek at sales numbers is sending Apple upwards for the second straight session.

The technical picture has something to do with Apple’s price strength here. Shares are breaking above an important resistance level up at $111, a price level that’s acted like a ceiling for shares since April. From here, prior highs around $120 look like the next target for Apple to take out on the way up.

Meanwhile, Ford Motor (F)  is correcting nearly 2% this afternoon following the announcement that financial performance is set to decline next year as it increases spending on driverless and electric cars. The R&D bump is planned to help Ford push its way to a planned 2021 introduction of a driverless car, a product intro that the firm sees as a material contributor to its overall business in the years ahead.

Technically speaking, Ford’s correction today is the latest in a series. Shares have been in a downtrend for much of 2016, and today’s drop only brings this stock a little closer to trendline support at $11.75. Until Ford can start establishing some higher lows, it makes sense to steer clear of this stock for the time being.

Monsanto  (MON)  is one of the biggest stock stories this afternoon, up slightly following news that Bayer AG had agreed to buy the firm in a deal valued at $66 billion. That update finishes four months of negotiations that will create the world’s biggest agrichemical business. Bayer will pay $128 per share in cash for Monsanto, an offer price that still represents about a 20% premium to shares’ current trading price. That gap between the offer price and Monsanto’s current trading range represents the risks that Wall Street is pricing in that regulatory hurdles will get in the way of the acquisition being completed. In the meantime, the companies expect the deal to be completed by the end of next year.

With considerable room left on the way up to Monsanto’s offer price, this stock’s uptrend looks particularly important. If shares keep bouncing their way higher from a technical standpoint, then this stock could still rally appreciably before hitting any meaningful amount of resistance.

Original Article: The Street.com 
Jonas Elmerraji Sep 14, 2016


No Comments

Post A Comment